This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.

Ubc9

From Proteopedia

(Difference between revisions)

Jump to: navigation, search

Revision as of 23:34, 24 February 2015

Ubc9 is a ubiquitin conjugating enzyme (E2) whose function involves transfer of ubiquitin or small ubiquitin-like modifier (SUMO) from ubiquitin activating enzyme (E1) to its designated substrate. Ubc9 is specifically involved in SUMO transfer ^[1].

1 Structure
2 Function
3 Disease
4 Relevance
5 Structural highlights

Structure

Murine/human Ubc9 exhibits a single domain structure consisting of both alpha helices and beta-pleated sheets (PDB: 1U9A). has been identified as the active residue and is located on a loop of amino acids (78-108) between beta sheet four and alpha helix two ^[1]. Crystal structure of the noncovalent interaction between Ubc9 and SUMO1 have shown that the Ubc9 residues involved in this interaction are located at the end of helix one, on beta strand one, and along the following loop. These residues were shown to interact with the beta sheet of SUMO1 ^[2].

Function

Ubc9 is a part of the SUMOylation process. It is the enzyme responsible for ligating the SUMO to the protein. Depending on whether the reaction is done in vitro, it will ligate the SUMO directly to the substrate, and if done in vivo, the SUMO will be ligated to the conjugating enzyme and then put onto the substrate [2]. Mutagenesis studies on Ubc9 SUMO1 complex have shown that Ubc9H20D and SUMO1E67R mutation cause inhibition of noncovalent interaction between the two, and thus inhibit complex formation. A similar interaction is seen in the Ubc9-SUMO2 complex ^[2]. Lack of noncovalent interaction between Ubc9 and SUMO2 has been shown to inhibit SUMO2 chain formation. This chain formation is critical for in vivo function, in which formation of ubiquitin or SUMO chains results in cellular processes such as protein degradation ^[2].

Disease

Expression of Ubc9 has been found to be related to causing human diseases such as cancer, neurodegenerative diseases, and heart diseases. Studies have shown it to interact with tumor suppressor proteins such as p53, p63, and p73 and fundamental in the tumor progression and preventing apoptotic pathways. [3]

Relevance

Structural highlights

Anything in this section will appear adjacent to the 3D structure and will be scrollable.

References

↑ ^1.0 ^1.1 Tong H, Hateboer G, Perrakis A, Bernards R, Sixma TK. Crystal structure of murine/human Ubc9 provides insight into the variability of the ubiquitin-conjugating system. J Biol Chem. 1997 Aug 22;272(34):21381-7. PMID:9261152
↑ ^2.0 ^2.1 ^2.2 Knipscheer P, van Dijk WJ, Olsen JV, Mann M, Sixma TK. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. EMBO J. 2007 Jun 6;26(11):2797-807. Epub 2007 May 10. PMID:17491593

Proteopedia Page Contributors and Editors (what is this?)

Byron H. Young, Saieh Bijani, Michal Harel

Retrieved from "http://52.214.119.220/wiki/index.php/Ubc9"

Revision as of 23:33, 24 February 2015 (edit) Byron H. Young (Talk \| contribs) ← Previous diff		Revision as of 23:34, 24 February 2015 (edit) (undo) Byron H. Young (Talk \| contribs) Next diff →
Line 5:		Line 5:
	== Structure ==		== Structure ==

-	Murine/human ''Ubc9'' exhibits a single domain structure consisting of both alpha helices and beta-pleated sheets (PDB: 1U9A). <scene name='69/694804/Cys93/1'>Cys93</scene> has been identified as the active residue and is located on a loop of amino acids (78-108) between beta sheet four and alpha helix two <ref name="crystal"/>. Crystal structure of the noncovalent interaction between ''Ubc9'' and SUMO1 have shown that the Ubc9 residues involved in this interaction are located at the end of helix one, on beta strand one, and along the following loop. These residues were shown to interact with the beta sheet of SUMO1 <ref name="ubcsumocomplex">PMID:17491593</ref>.	+	Murine/human ''Ubc9'' exhibits a single domain structure consisting of both alpha helices and beta-pleated sheets (PDB: 1U9A). <scene name='69/694804/Cys93/5'>Cys93</scene> has been identified as the active residue and is located on a loop of amino acids (78-108) between beta sheet four and alpha helix two <ref name="crystal"/>. Crystal structure of the noncovalent interaction between ''Ubc9'' and SUMO1 have shown that the Ubc9 residues involved in this interaction are located at the end of helix one, on beta strand one, and along the following loop. These residues were shown to interact with the beta sheet of SUMO1 <ref name="ubcsumocomplex">PMID:17491593</ref>.

Ubc9

From Proteopedia

Revision as of 23:34, 24 February 2015

Contents

Structure

Function

Disease

Relevance

Structural highlights

References

Proteopedia Page Contributors and Editors (what is this?)

Views

Personal tools

Navigation

Search

Toolbox